Forward Looking Statement & Non-GAAP Disclaimer

This presentation may contain forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Colfax’s plans, objectives, outlook, expectations and intentions, including the intended separation of Colfax’s fabrication technology and specialty medical technology businesses (the “Separation”), and the timing, method and anticipated benefits of the Separation, the expected benefits of acquisitions, and other statements that are not historical or current fact. Forward-looking statements are based on Colfax’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Colfax’s results to differ materially from current expectations include, but are not limited to, risks related to the impact of the COVID-19 global pandemic, including the rise, prevalence and severity of variants of the virus, actions by governments, the scope and duration of the outbreak, the nature and effectiveness of government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions, the impact on creditworthiness and financial viability of customers; risks relating to the Separation, including the final approval of the Separation by Colfax’s board of directors, the uncertainty of obtaining regulatory approvals, and a favorable tax opinion and ruling from the Internal Revenue Service, Colfax’s ability to satisfactorily complete all steps necessary for the Separation and related transactions to be generally tax-free for U.S. federal income tax purposes, the ability to satisfy the necessary conditions to complete the Separation on a timely basis, or at all, the ability to realize the anticipated benefits of the Separation, developments related to the impact of the COVID-19 pandemic on the Separation, and the financial and operating performance of each company following the Separation; other impacts on Colfax’s business and ability to execute business continuity plans; and the company’s reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks discussed in Colfax’s filings with the SEC.

In addition, these statements are based on assumptions that are subject to change. This presentation speaks only as of the date hereof. Colfax disclaims any duty to update the information herein.

The term “Colfax” in reference to the activities described in this presentation may mean one or more of Colfax’s global operating subsidiaries and/or their internal business divisions and does not necessarily indicate activities engaged in by Colfax Corporation.

Colfax has provided in this presentation financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America (“non-GAAP”). These non-GAAP financial measures may include one or more of the following: adjusted net income from continuing operations, adjusted net income margin from continuing operations, adjusted net income per diluted share from continuing operations, adjusted EBITA (earnings before interest, taxes and amortization), adjusted EBITDA (adjusted EBITA plus depreciation and other amortization), adjusted EBITA margin, adjusted EBITDA margin, organic sales growth, and free cash flow. Colfax also provides adjusted EBIT, adjusted EBITDA, adjusted EBITA margin and adjusted EBITDA margin on a segment basis. Colfax also provides organic adjusted EBITDA which represents the existing business excluding the impacts of acquisitions made since Q4 of 2020

- Adjusted net income from continuing operations represents net income (loss) from continuing operations excluding restructuring and other related charges, European Union Medical Device Regulation ("MDR") and other costs, pension settlement gain, debt extinguishment charges, acquisition-related amortization and other non-cash charges, and strategic transaction costs. Adjusted net income includes the tax effect of adjusted pre-tax income at applicable tax rates and other tax adjustments. Colfax also presents adjusted net income margin from continuing operations, which is subject to the same adjustments as adjusted net income from continuing operations.
- Adjusted net income per diluted share from continuing operations represents adjusted net income from continuing operations divided by the number of adjusted diluted weighted average shares. Both GAAP and non-GAAP diluted net income per share data are computed based on weighted average shares outstanding and, if there is net income from continuing operations (rather than net loss) during the period, the dilutive impact of share equivalents outstanding during the period. Diluted weighted average shares outstanding is based on adjusted diluted weighted average shares outstanding computed using the number of net income or loss figure except in determining the effect of dilutive shares.
- Adjusted EBITA represents net income (loss) from continuing operations excluding restructuring and other related charges, MDR and other costs, acquisition-related amortization and other non-cash charges, and strategic transaction costs, as well as income tax expense (benefit) and interest expense. net. Colfax presents adjusted EBITA margin, which is subject to the same adjustments as adjusted EBITA. Further, Colfax presents adjusted EBITA and adjusted EBITA margin on a segment basis, which excludes the impact of strategic transaction costs and acquisition-related amortization and other non-cash charges from segment operating income.
- Organic sales growth (decline) excludes the impact of acquisitions and foreign exchange rate fluctuations. Organic sales per-day growth (decline) represents Organic sales growth (decline) adjusted for additional or fewer selling days calculated based on the global average selling days particular to each segment.
- Free cash flow represents cash flow from operating activities excluding cash outflows related to the planned separation, less purchases of property, plant and equipment from sale of certain properties.

These non-GAAP financial measures assist Colfax management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of the Company. Colfax management also believes that presenting these measures allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures provided in the appendix to this presentation.

In this presentation, Colfax presents forward-looking adjusted EPS, adjusted EBITDA and free cash flow guidance. Colfax does not provide such outlook on a GAAP basis because changes in the items that Colfax excludes from GAAP to calculate adjusted EPS can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of Colfax’s routine operating activities. Additionally, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on an outlook done on a GAAP basis. These excluded items could have a significant impact on the Company’s GAAP financial results.
ESAB and Enovis to host investor calls on Monday, March 14, 2022 to outline their separate plans for attractive growth and value creation

- ESAB: 9:00 a.m. to 10:30 a.m. Eastern Time
- 30-minute break
- Enovis: 11:00 a.m. to 1:00 p.m. Eastern Time

For more information, please visit the Investor Relations section of our website: [https://ir.colfaxcorp.com/events-presentations](https://ir.colfaxcorp.com/events-presentations)

A replay of these calls will also be available on Colfax’s website following the event
FY 2021 Performance Highlights

- Delivered our commitments with aEPS of $2.14, aEBITDA of $614mm and free cash flow of $277mm\(^1\)
  - Accelerating pace of investment and innovation
  - MedTech / Enovis and ESAB outgrew their markets
- Both businesses made progress on their margin improvement journeys in inflationary environment
  - ESAB aEBITDA margins improved 150 bps to 17.9%
  - Medtech core (ex-acq) aEBITDA margins improved 80 bps to 18.8%
- Completed several acquisitions to accelerate growth and create new long-term growth opportunities
- Strong progress made to separate Colfax into two independent public companies

Businesses are well-positioned strategically, operationally and financially for separation

\(^1\) Excludes separation costs and includes proceeds from sale of certain properties
Refer to Appendix for non-GAAP reconciliations and footnotes.
Strong Market Outperformance in Both Businesses

**Enovis: Outperforming Peers**

- **Reconstructive**
  - 2021 vs 2019 organic growth
  - 7%*
  - Recon Peers Avg. Relevant Growth
  - Enovis

- **P&R**
  - 2021 vs 2019 organic growth
  - 0%*
  - P&R Peers Avg. Relevant Growth
  - Enovis

**ESAB: Outperforming Peers**

- **2019 Yr-Yr Organic Growth**
  - ESAB: 2%
  - Peer Avg: -2%
  - Enovis: Outperforming Peers

- **2020 Yr-Yr Organic Growth**
  - ESAB: -10%
  - Peer Avg: -12%
  - Enovis: Outperforming Peers

- **2021 Yr-Yr Organic Growth**
  - ESAB: 23%
  - Peer Avg: 19%
  - Enovis: Outperforming Peers

* Growth on a sales per day basis
Refer to Appendix for non-GAAP reconciliations and footnotes.

Consistently driving above-market growth
Q4 2021 Highlights

- Q4 total sales growth of 24%, 16% organic sales-per-day (SPD), outgrew markets across both businesses
  - MedTech +10% organic sales-per-day
  - ESAB +20% organic sales-per-day
- Increased aEBITDA 16% yr-yr to $164mm
- Achieved aEPS of $0.59, +16% vs prior year
- Key separation activities on track for completion near the end of the first quarter 2022

Strong Q4 execution, positioned for strong growth in 2022

Refer to Appendix for non-GAAP reconciliations and footnotes.
Most steps required to make the separation have been completed

Capital structures expected to provide each business with resources & flexibility to achieve long-term strategic goals

- Bank credit agreements fully committed
- Enovis to launch with significant capacity for acquisitive growth
  - Colfax (will be renamed Enovis upon separation) intends to distribute 90% of outstanding shares in ESAB to Colfax shareholders at the time of separation and exchange the 10% stake within 12 months of the separation, resulting in a debt-free balance sheet*
- ESAB is expected to launch with strong free cash flow and net debt equal to approximately 2.75x of its trailing aEBITDA or ~$1.2 billion

Two strong and diverse Boards of Directors

- Expect mix of existing Colfax directors and new directors with relevant skills and experiences
- Mitch Rales, current Colfax Chairman, is expected to serve as Chairman of both business’ boards

* Before new acquisition investments, if any
MedTech Q4 Update

Sales

- **Q4 organic SPD growth of 10%, 2% growth vs 2019**, with balanced growth across both businesses
- Sales pressured by COVID, particularly in December as cases increased due to the Omicron variant
- **Recon sales growth +80% (cc), +10% organic SPD**
  - Strong growth across product portfolio, highlighted by mid-teen organic growth in knee implants
  - Mathys and Foot & Ankle acquisitions performing well
- **P&R sales growth +14% (cc), +10% organic SPD**
  - Global Bracing growth of low double-digits, with balanced growth in US and International

Market outperformance in both Recon and P&R
Finished 2021 with strong growth and margin momentum

- **Strong Q4 performance with 20% organic SPD growth**
- **Americas (+31% organic, volume +10%)**
  - Healthy demand within most end markets
  - New product introductions driving incremental demand
- **EMEA & APAC (+16% organic, volume +6%)**
  - Strong momentum in equipment sales
- Innovation and local presence driving share gain and competitive advantage
- Dynamically using price to offset inflation and effectively managing global supply constraints
### Q4 2021 Financial Highlights

**Millions, except for EPS**

<table>
<thead>
<tr>
<th></th>
<th>Q4 2020</th>
<th>Q4 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Sales</td>
<td>$828</td>
<td>$1,023</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>$355</td>
<td>$419</td>
</tr>
<tr>
<td>Gross Margin</td>
<td>42.8%</td>
<td>40.9%</td>
</tr>
<tr>
<td>Adj. EBITA</td>
<td>$113</td>
<td>$136</td>
</tr>
<tr>
<td>Adj. EBITA Margin</td>
<td>13.6%</td>
<td>13.3%</td>
</tr>
<tr>
<td>Adj. EBITDA</td>
<td>$142</td>
<td>$164</td>
</tr>
<tr>
<td>Adj. EBITDA Margin</td>
<td>17.1%</td>
<td>16.1%</td>
</tr>
<tr>
<td>Adj. EPS</td>
<td>$0.51</td>
<td>$0.59</td>
</tr>
<tr>
<td>Free Cash Flow*</td>
<td>$96</td>
<td>$85</td>
</tr>
</tbody>
</table>

- Achieved sales growth of 24%
  - 18% organic, 7% acquisitions, -1% FX
  - MedTech and ESAB volumes both grew over 2019 levels
- Gross margins included ~240 bps compression from price/inflation pass-through at ESAB; gross profit protected with dynamic pricing actions
- Organic aEBITA margins increased 20 bps yr-yr excluding the impact of recent acquisitions that are expected to scale with fast growth
- Q4 adjusted effective tax rate of 19%, full year rate of 22%
- Strong Q4 cash flow performance, FY 2021 free cash flow of $277mm*

*Free cash flow represents cash flow from operating activities excluding cash outflows related to the planned separation, less purchases of property, plant and equipment net proceeds from sale of certain properties. Refer to Appendix for non-GAAP reconciliation and footnotes.

**Strong execution and growth, momentum entering 2022**
MedTech Q4 2021 Financial Highlights

- Q4 sales increased 29%; organic sales-per-day increased ~10% and FX headwind of ~1pts
  - Substantial growth contribution from recent acquisitions & beating competition
- Strong operational execution in the quarter with 50 bps core aEBITA margin expansion vs. prior year
  - Margin pressure from continued inflation and supply chain challenges offset by pricing actions and cost control measures
- Solid aEBITDA\(^1\) progression throughout the year

Sequential core margin improvements throughout 2021

1 Core figures are from existing businesses and exclude the impacts of acquisitions that have not yet annualized. Refer to Appendix for non-GAAP reconciliation and footnotes.
ESAB Q4 2021 Financial Highlights

Total sales grew 20%
- Healthy growth across developed and developing regions, 7 pts of volume
- Pricing standard work offsetting inflation pressures, 15 pts of price
- FX headwind of 2pts

Strong operational execution in the quarter with 60 bps aEBITA margin expansion despite margin pressure from continued inflationary pricing
- Maintained customer delivery performance
- Structural cost actions

Continuing to deliver on the top and bottom lines

Refer to Appendix for non-GAAP reconciliation and footnotes.
**2022 Segment-Level Outlook**

### FabTech / ESAB

<table>
<thead>
<tr>
<th>Sales $bn</th>
<th>Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>$2.43</td>
</tr>
<tr>
<td>2022 est.</td>
<td>$2.55-$2.60</td>
</tr>
</tbody>
</table>

- Reported: +5% - 7%
- Organic Growth: +7% - 10%
- FX Impact: (2%) - (3%)

**Segment-level aEBITDA $mm**

| 2021     | $434        |
| 2022 est. | $455-$475   |

**MedTech / Enovis**

<table>
<thead>
<tr>
<th>Sales $bn</th>
<th>Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>$1.43</td>
</tr>
<tr>
<td>2022 est.</td>
<td>$1.57-$1.63</td>
</tr>
</tbody>
</table>

- Reported: +10% - 14%
- Organic Growth: +6% - 9%
- Acquisitions: +5% - 6%
- FX Impact: ~(1%)%

**Segment-level aEBITDA $mm**

| 2021     | $254        |
| 2022 est. | $280-$300   |

Excludes corporate costs

*Expecting strong sales and EBITDA growth*

Refer to Appendix for non-GAAP reconciliation and footnotes.
Q4 was a strong finish to a pivotal year at Colfax
- Another quarter of outperforming our markets and expanding our margins
- Effective delivery of cash flow

ESAB and Enovis are ready for their strong value creation paths
- Strong strategies, leadership and tailored capital structures
- On track for separation in early April

Both businesses have attractive 2022 outlooks
- Healthy growth and improving markets
- Margin improvements

We look forward to our Monday, March 14th investor calls
- Deeper dive on strategies for profitable growth, 2022 outlooks

Both businesses are well-positioned for the separation with strong momentum
Appendix
Non-GAAP Reconciliation

<table>
<thead>
<tr>
<th>Colfax Corporation</th>
<th>Three Months Ended</th>
<th>Year Ended</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>December 31, 2021</td>
<td>December 31, 2020</td>
</tr>
<tr>
<td>Adjusted Net Income and Adjusted Net Income Per Share</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net income from continuing operations attributable to Colfax Corporation (GAAP)</td>
<td>$10.2</td>
<td>$40.6</td>
</tr>
<tr>
<td>Restructuring and other related charges - pretax</td>
<td>16.9</td>
<td>16.5</td>
</tr>
<tr>
<td>MDR and other costs - pretax</td>
<td>2.4</td>
<td>2.4</td>
</tr>
<tr>
<td>Debt extinguishment charges - pretax</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Acquisitions-related amortization and other non-cash charges - pretax</td>
<td>44.8</td>
<td>35.8</td>
</tr>
<tr>
<td>Strategic transaction costs - pretax</td>
<td>16.7</td>
<td>(0.4)</td>
</tr>
<tr>
<td>Pension settlement loss (gain) - pretax</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tax adjustment</td>
<td>5.1</td>
<td>(24.4)</td>
</tr>
<tr>
<td>Adjusted net income from continuing operations (non-GAAP)</td>
<td>$96.0</td>
<td>$70.6</td>
</tr>
</tbody>
</table>

| Adjusted net income per share - diluted from continuing operations (non-GAAP) | | | |
| Adjusted net income per share - diluted from continuing operations (GAAP) | $0.59 | $0.51 | $2.14 |

---

(1) Net income from continuing operations attributable to Colfax Corporation for the respective periods is calculated using Net income (loss) from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes, of $1.4 and $0.9 for the three months ended December 31, 2021 and December 31, 2020, respectively; and $4.6, $3.1, and $4.6 for the years ended December 31, 2021, December 31, 2020 and December 31, 2019, respectively.

(2) Restructuring and other related charges includes $5.2 and $1.7 of expense classified as Cost of sales on our Consolidated Statements of Operations for the three months ended December 31, 2021 and December 31, 2020, respectively; and $5.2, $6.6, and $8.5 of expense classified as Cost of sales on our Consolidated Statements of Operations for the years ended December 31, 2021, December 31, 2020 and December 31, 2019, respectively.

(3) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.

(4) Includes amortization of acquired intangibles and fair value charges on acquired inventory.

(5) For the three months and year ended December 31, 2021, Strategic transaction costs includes costs related to the planned separation and certain transaction and integration costs related to recent acquisitions. For the three months and year ended December 31, 2020, and the year ended December 31, 2019, Strategic transaction costs includes costs incurred for the acquisition of DJO.

(6) The effective tax rates used to calculate adjusted net income and adjusted net income per share were 19.2% and 18.0% for the three months ended December 31, 2021 and December 31, 2020, respectively; and 22.1%, 23.3%, and 21.9% for the years ended December 31, 2021, December 31, 2020 and December 31, 2019, respectively.

---

Note: Dollars in millions. Some periods may not foot due to rounding.
Non-GAAP Reconciliation

<table>
<thead>
<tr>
<th></th>
<th>Fabrication Technology</th>
<th>Medical Technology</th>
<th>Total Colfax Corporation</th>
</tr>
</thead>
<tbody>
<tr>
<td>For the three months ended December 31, 2020</td>
<td>$ 518.6</td>
<td>$ 890.5</td>
<td>$ 828.1</td>
</tr>
</tbody>
</table>

Components of change:

<table>
<thead>
<tr>
<th></th>
<th>Fabrication Technology</th>
<th>Medical Technology</th>
<th>Total Colfax Corporation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Existing businesses(^1)</td>
<td>134.1</td>
<td>34.5</td>
<td>148.6</td>
</tr>
<tr>
<td>Acquisitions(^2)</td>
<td>0.5</td>
<td>57.1</td>
<td>57.6</td>
</tr>
<tr>
<td>Foreign currency translation(^3)</td>
<td>(9.0)</td>
<td>(2.0)</td>
<td>(11.0)</td>
</tr>
<tr>
<td></td>
<td>105.6</td>
<td>89.6</td>
<td>195.2</td>
</tr>
</tbody>
</table>

For the three months ended December 31, 2021

<table>
<thead>
<tr>
<th></th>
<th>Fabrication Technology</th>
<th>Medical Technology</th>
<th>Total Colfax Corporation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$ 624.2</td>
<td>$ 993.1</td>
<td>$ 1,023.3</td>
</tr>
</tbody>
</table>

\(^1\) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of growth due to factors such as price and volume. Includes the favorable sales impact of approximately 2% in both the Fabrication Technology and Medical Technology segments due to additional selling days, calculated based on the global average selling days particular to each segment.

\(^2\) Represents the incremental sales in comparison to the portion of the prior period during which we did not own the business.

\(^3\) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.

Note: Dollars in millions. Some periods may not foot due to rounding.
Non-GAAP Reconciliation

<table>
<thead>
<tr>
<th>Net Sales</th>
<th>Fabrication Technology</th>
</tr>
</thead>
<tbody>
<tr>
<td>For the year ended December 31, 2018</td>
<td>$ 2,191.5</td>
</tr>
<tr>
<td>Components of change:</td>
<td></td>
</tr>
<tr>
<td>Existing businesses(^{(1)})</td>
<td>21.8</td>
</tr>
<tr>
<td>Acquisitions(^{(2)})</td>
<td>159.3</td>
</tr>
<tr>
<td>Foreign currency translation(^{(3)})</td>
<td>(87.1)</td>
</tr>
<tr>
<td></td>
<td>54.0</td>
</tr>
<tr>
<td>For the year ended December 31, 2019</td>
<td>$ 2,447.0</td>
</tr>
<tr>
<td>Components of change:</td>
<td></td>
</tr>
<tr>
<td>Existing businesses(^{(1)})</td>
<td>(218.4)</td>
</tr>
<tr>
<td>Acquisitions(^{(2)})</td>
<td>-</td>
</tr>
<tr>
<td>Foreign currency translation(^{(3)})</td>
<td>(75.8)</td>
</tr>
<tr>
<td></td>
<td>(294.9)</td>
</tr>
<tr>
<td>For the year ended December 31, 2020</td>
<td>$ 1,652.1</td>
</tr>
<tr>
<td>Components of change:</td>
<td></td>
</tr>
<tr>
<td>Existing businesses(^{(1)})</td>
<td>455.6</td>
</tr>
<tr>
<td>Acquisitions(^{(2)})</td>
<td>2.1</td>
</tr>
<tr>
<td>Foreign currency translation(^{(3)})</td>
<td>10.2</td>
</tr>
<tr>
<td></td>
<td>473.0</td>
</tr>
<tr>
<td>For the year ended December 31, 2021</td>
<td>$ 2,428.3</td>
</tr>
</tbody>
</table>

\(^{(1)}\) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of growth due to factors such as price and volume.

\(^{(2)}\) Represents the incremental sales in comparison to the portion of the prior period during which we did not own the business.

\(^{(3)}\) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.

\*Note: Dollars in millions. Some periods may not foot due to rounding.*
Non-GAAP Reconciliation

### Notes:

1. Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.

2. For the three months ended December 31, 2021, Strategic transaction costs includes costs related to the planned separation and certain transaction and integration costs related to recent acquisitions. For the three months ended December 31, 2020, Strategic transaction costs includes costs incurred for the acquisition of DJO.

3. Includes amortization of acquired intangibles and fair value charges on acquired inventory.

4. Restructuring and other related charges in the Medical Technology segment includes $5.2 and $1.7 of expense classified as Cost of sales on the Company’s Consolidated Statements of Operations for the three months ended December 31, 2021 and December 31, 2020, respectively.

---

**Three Months Ended December 31, 2021**

<table>
<thead>
<tr>
<th></th>
<th>Fabrication Technology</th>
<th>Medical Technology</th>
<th>Corporate and Other</th>
<th>Total Colfax</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net sales</strong></td>
<td>$824.2</td>
<td>$599.1</td>
<td>$ -</td>
<td>$1,023.3</td>
</tr>
<tr>
<td><strong>Operating income (loss) (GAAP)</strong></td>
<td>86.8</td>
<td>13.0%</td>
<td>10.8</td>
<td>2.7%</td>
</tr>
<tr>
<td>Restructuring and other related charges</td>
<td>8.2</td>
<td></td>
<td>8.7</td>
<td></td>
</tr>
<tr>
<td>MDR and other costs(1)</td>
<td></td>
<td></td>
<td>2.4</td>
<td></td>
</tr>
<tr>
<td><strong>Segment operating income (loss) (non-GAAP)</strong></td>
<td>89.0</td>
<td>14.3%</td>
<td>21.9</td>
<td>3.5%</td>
</tr>
<tr>
<td>Strategic transaction costs(2)</td>
<td>2.0</td>
<td></td>
<td>2.7</td>
<td></td>
</tr>
<tr>
<td>Acquisition-related amortization and other non-cash charges(3)</td>
<td>8.8</td>
<td></td>
<td>35.9</td>
<td></td>
</tr>
<tr>
<td><strong>Adjusted EBITA (non-GAAP)</strong></td>
<td>$99.9</td>
<td>16.0%</td>
<td>60.5</td>
<td>15.2%</td>
</tr>
<tr>
<td>Depreciation and other amortization</td>
<td>9.5</td>
<td></td>
<td>18.5</td>
<td></td>
</tr>
<tr>
<td><strong>Adjusted EBITDA (non-GAAP)</strong></td>
<td>$109.4</td>
<td>17.5%</td>
<td>79.0</td>
<td>19.8%</td>
</tr>
</tbody>
</table>

---

**Three Months Ended December 30, 2020**

<table>
<thead>
<tr>
<th></th>
<th>Fabrication Technology</th>
<th>Medical Technology</th>
<th>Corporate and Other</th>
<th>Total Colfax</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net sales</strong></td>
<td>$518.6</td>
<td>$309.3</td>
<td>$ -</td>
<td>$828.1</td>
</tr>
<tr>
<td><strong>Operating income (loss) (GAAP)</strong></td>
<td>60.1</td>
<td>11.6%</td>
<td>14.5</td>
<td>4.7%</td>
</tr>
<tr>
<td>Restructuring and other related charges(1)</td>
<td>10.2</td>
<td></td>
<td>6.3</td>
<td></td>
</tr>
<tr>
<td>MDR and other costs(1)</td>
<td></td>
<td></td>
<td>2.4</td>
<td></td>
</tr>
<tr>
<td><strong>Segment operating income (loss) (non-GAAP)</strong></td>
<td>70.3</td>
<td>13.6%</td>
<td>23.2</td>
<td>3.5%</td>
</tr>
<tr>
<td>Strategic transaction costs(2)</td>
<td>-</td>
<td></td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Acquisition-related amortization and other non-cash charges(3)</td>
<td>9.6</td>
<td></td>
<td>26.3</td>
<td></td>
</tr>
<tr>
<td><strong>Adjusted EBITA (non-GAAP)</strong></td>
<td>$79.9</td>
<td>15.4%</td>
<td>49.5</td>
<td>16.0%</td>
</tr>
<tr>
<td>Depreciation and other amortization</td>
<td>9.5</td>
<td></td>
<td>19.3</td>
<td></td>
</tr>
<tr>
<td><strong>Adjusted EBITDA (non-GAAP)</strong></td>
<td>$89.5</td>
<td>17.2%</td>
<td>68.8</td>
<td>22.3%</td>
</tr>
</tbody>
</table>

---

*Note: Dollars in millions. Some periods may not foot due to rounding.*
Non-GAAP Reconciliation

<table>
<thead>
<tr>
<th></th>
<th>Fabrication Technology</th>
<th>Medical Technology</th>
<th>Corporate and Other</th>
<th>Total Colfax</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year Ended December 31, 2021</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net sales</td>
<td>$2,428.1</td>
<td>$1,426.2</td>
<td>$ -</td>
<td>$3,854.3</td>
</tr>
<tr>
<td>Operating income (loss) (GAAP)</td>
<td>357.4</td>
<td>13.9%</td>
<td>3.1%</td>
<td>(112.0)</td>
</tr>
<tr>
<td>Restructuring and other related charges(1)</td>
<td>19.0</td>
<td>13.9</td>
<td>-</td>
<td>32.9</td>
</tr>
<tr>
<td>MDR and other costs(3)</td>
<td>-</td>
<td>7.9</td>
<td>-</td>
<td>7.9</td>
</tr>
<tr>
<td>Segment operating income (loss) (non-GAAP)</td>
<td>356.3</td>
<td>14.7%</td>
<td>5.1%</td>
<td>(112.0)</td>
</tr>
<tr>
<td>Strategic transaction costs(4)</td>
<td>2.9</td>
<td>3.7%</td>
<td>-</td>
<td>44.0</td>
</tr>
<tr>
<td>Acquisition-related amortization and other non-cash charges(4)</td>
<td>35.9</td>
<td>127.7</td>
<td>37.3</td>
<td>163.6</td>
</tr>
<tr>
<td>Adjusted EBITA (non-GAAP)</td>
<td>$395.1</td>
<td>16.3%</td>
<td>12.9%</td>
<td>(74.7)</td>
</tr>
<tr>
<td>Depreciation and other amortization</td>
<td>38.5</td>
<td>69.6</td>
<td>1.2</td>
<td>109.3</td>
</tr>
<tr>
<td>Adjusted EBITDA (non-GAAP)</td>
<td>$433.6</td>
<td>17.9%</td>
<td>17.8%</td>
<td>(73.4)</td>
</tr>
</tbody>
</table>

(1) Restructuring and other related charges in the Medical Technology segment includes $5.2 of expense classified as Cost of sales on the Company’s Consolidated Statements of Operations.
(2) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.
(3) Strategic transaction costs includes costs related to the Separation and certain transaction and integration costs related to recent acquisitions.
(4) Includes amortization of acquired intangibles and fair value charges on acquired inventory.

Note: Dollars in millions. Some periods may not foot due to rounding.
Non-GAAP Reconciliation

Note: Dollars in millions. Some periods may not foot due to rounding.

<table>
<thead>
<tr>
<th>Year Ended December 31, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Net sales</td>
</tr>
<tr>
<td>Operating income (loss) (GAAP)</td>
</tr>
<tr>
<td>Restructuring and other related charges(1)</td>
</tr>
<tr>
<td>MDR and other costs(2)</td>
</tr>
<tr>
<td>Segment operating income (loss) (non-GAAP)</td>
</tr>
<tr>
<td>Strategic transaction costs(3)</td>
</tr>
<tr>
<td>Acquisition-related amortization and other non-cash charges(4)</td>
</tr>
<tr>
<td>Adjusted EBITA (non-GAAP)</td>
</tr>
<tr>
<td>Depreciation and other amortization</td>
</tr>
<tr>
<td>Adjusted EBITDA (non-GAAP)</td>
</tr>
</tbody>
</table>

(1) Restructuring and other related charges in the Medical Technology segment includes $6.6 of expense classified as Cost of sales on the Company’s Consolidated Statements of Operations.
(2) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.
(3) Strategic transaction costs includes costs incurred for the acquisition of DJO.
(4) Includes amortization of acquired intangibles and fair value charges on acquired inventory.
Restructuring and other related charges in the Medical Technology segment includes $8.5 of expense classified as Cost of sales on the Company’s Consolidated Statements of Operations.

Strategic transaction costs includes costs incurred for the acquisition of DJO.

Includes amortization of acquired intangibles and fair value charges on acquired inventory.
### Non-GAAP Reconciliation

<table>
<thead>
<tr>
<th></th>
<th>April 3, 2021</th>
<th>July 2, 2021</th>
<th>October 1, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net sales</strong></td>
<td>$511.1</td>
<td>$356.1</td>
<td>$359.9</td>
</tr>
<tr>
<td><strong>Operating income (loss) (GAAP)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restructuring and other related charges</td>
<td>(0.6)</td>
<td>1.0</td>
<td>1.8</td>
</tr>
<tr>
<td>MDR and other costs (1)</td>
<td></td>
<td>14.3</td>
<td>2.0</td>
</tr>
<tr>
<td><strong>Segment operating income (loss) (non-GAAP)</strong></td>
<td>2.2</td>
<td>2.0</td>
<td>1.9</td>
</tr>
<tr>
<td>Strategic transaction costs (2)</td>
<td></td>
<td>18.2</td>
<td>1.9</td>
</tr>
<tr>
<td>Acquisition-related amortization and other non-cash charges (3)</td>
<td>2.2</td>
<td>2.2</td>
<td>2.2</td>
</tr>
<tr>
<td><strong>Adjusted EBITA (non-GAAP)</strong></td>
<td></td>
<td>29.4</td>
<td>29.9</td>
</tr>
<tr>
<td>Depreciation and other amortization</td>
<td></td>
<td>16.7</td>
<td>16.2</td>
</tr>
<tr>
<td><strong>Adjusted EBITDA (non-GAAP)</strong></td>
<td></td>
<td>48.3</td>
<td>44.4</td>
</tr>
</tbody>
</table>

(1) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.
(2) Strategic transaction costs includes costs related to the planned separation and certain transaction and integration costs related to recent acquisitions.
(3) Includes amortization of acquired intangibles and fair value charges on acquired inventory.

**Note:** Dollars in millions. Some periods may not foot due to rounding.
## Non-GAAP Reconciliation

<table>
<thead>
<tr>
<th></th>
<th>Year Ended December 31, 2021</th>
<th>Colfax Corporation Nineteen Months Ended October 1, 2021</th>
<th>Three Months Ended December 31, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net cash provided by operating activities</td>
<td>$356.1</td>
<td>$259.9</td>
<td>$95.2</td>
</tr>
<tr>
<td>Purchases of property, plant and equipment</td>
<td>(104.2)</td>
<td>(75.6)</td>
<td>(30.6)</td>
</tr>
<tr>
<td>Payments related to the Separation</td>
<td>22.2</td>
<td>6.3</td>
<td>15.9</td>
</tr>
<tr>
<td>Proceeds from sale of certain properties(^1)</td>
<td>3.2</td>
<td>-</td>
<td>3.2</td>
</tr>
<tr>
<td><strong>Free cash flow</strong></td>
<td><strong>$277.5</strong></td>
<td><strong>$192.6</strong></td>
<td><strong>$84.7</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Year Ended December 31, 2020</th>
<th>Colfax Corporation Nineteen Months Ended October 2, 2020</th>
<th>Three Months Ended December 31, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purchases of property, plant and equipment</td>
<td>(114.8)</td>
<td>(81.5)</td>
<td>(33.2)</td>
</tr>
<tr>
<td><strong>Free cash flow</strong></td>
<td><strong>$187.2</strong></td>
<td><strong>$91.6</strong></td>
<td><strong>$95.6</strong></td>
</tr>
</tbody>
</table>

\(^1\) Includes proceeds from the sale of certain properties related to restructuring efforts for which previous cash outlays were included in Net cash provided by operating activities.

---

**Note:** Dollars in millions. Some periods may not foot due to rounding.
## Non-GAAP Reconciliation

### Medical Technology (organic) (1)

<table>
<thead>
<tr>
<th></th>
<th>April 2, 2021</th>
<th>July 2, 2021</th>
<th>October 1, 2021</th>
<th>December 31, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net sales - organic</td>
<td>$279.1</td>
<td>$333.2</td>
<td>$314.5</td>
<td>$334.9</td>
</tr>
<tr>
<td>Operating income - organic (GAAP)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.2</td>
<td>17.7</td>
<td>14.4</td>
<td>18.1</td>
</tr>
<tr>
<td>Restructuring and other related charges - organic</td>
<td>5.1</td>
<td>5.0</td>
<td>3.8</td>
<td>10.9</td>
</tr>
<tr>
<td>Segment operating income - organic (non-GAAP)</td>
<td>5.3</td>
<td>20.7</td>
<td>18.2</td>
<td>29.0</td>
</tr>
<tr>
<td>Acquisition-related amortization and other non-cash charges - organic (2)</td>
<td>26.3</td>
<td>26.5</td>
<td>26.4</td>
<td>26.3</td>
</tr>
<tr>
<td>Adjusted EBITA - organic (non-GAAP)</td>
<td>$53.6</td>
<td>10.6%</td>
<td>$47.2</td>
<td>14.2%</td>
</tr>
<tr>
<td>Depreciation and other amortization - organic</td>
<td>16.0</td>
<td>15.2</td>
<td>15.0</td>
<td>15.7</td>
</tr>
<tr>
<td>Adjusted EBITDA - organic (non-GAAP)</td>
<td>$47.6</td>
<td>16.0%</td>
<td>$62.4</td>
<td>18.7%</td>
</tr>
</tbody>
</table>

### Medical Technology (organic) (2)

<table>
<thead>
<tr>
<th></th>
<th>December 31, 2021</th>
<th>December 31, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net sales - organic</td>
<td>$1,279.7</td>
<td>$1,133.5</td>
</tr>
<tr>
<td>Operating income - organic (GAAP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>52.4</td>
<td>(1.5)</td>
</tr>
<tr>
<td>Restructuring and other related charges - organic</td>
<td>20.8</td>
<td>28.9</td>
</tr>
<tr>
<td>Segment operating income - organic (non-GAAP)</td>
<td>73.2</td>
<td>27.4</td>
</tr>
<tr>
<td>Acquisition-related amortization and other non-cash charges - organic (2)</td>
<td>108.4</td>
<td>107.3</td>
</tr>
<tr>
<td>Adjusted EBITA - organic (non-GAAP)</td>
<td>$178.6</td>
<td>18.0%</td>
</tr>
<tr>
<td>Depreciation and other amortization - organic</td>
<td>62.5</td>
<td>64.5</td>
</tr>
<tr>
<td>Adjusted EBITDA - organic (non-GAAP)</td>
<td>$241.1</td>
<td>18.8%</td>
</tr>
</tbody>
</table>

(1) Organic figures are from existing businesses. Represents total sales less acquisition-related sales in comparison to the portion of the prior period during which we did not own the acquired businesses.

(2) Includes amortization of acquired intangibles and fair value charges on acquired inventory.

---

*Note: Dollars in millions. Some periods may not foot due to rounding.*
Non-GAAP Reconciliation

<table>
<thead>
<tr>
<th>Net sales - organic</th>
<th>December 31, 2021</th>
<th>December 31, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$ 959.1</td>
<td>$ 820.9</td>
</tr>
</tbody>
</table>

Operating Income (loss) - organic (GAAP)

<table>
<thead>
<tr>
<th>Restructuring and other related charges - organic</th>
<th>December 31, 2021</th>
<th>December 31, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>15.5</td>
<td>15.1</td>
</tr>
</tbody>
</table>

MDR and other costs - organic(2)

<table>
<thead>
<tr>
<th>MDR and other costs - organic(2)</th>
<th>December 31, 2021</th>
<th>December 31, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.4</td>
<td>2.4</td>
</tr>
</tbody>
</table>

Strategic transaction costs - organic(3)

<table>
<thead>
<tr>
<th>Strategic transaction costs - organic(3)</th>
<th>December 31, 2021</th>
<th>December 31, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>15.3</td>
<td>(0.4)</td>
</tr>
</tbody>
</table>

Acquisition-related amortization and other non-cash charges - organic(4)

<table>
<thead>
<tr>
<th>Acquisition-related amortization and other non-cash charges - organic(4)</th>
<th>December 31, 2021</th>
<th>December 31, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>32.4</td>
<td>35.5</td>
</tr>
</tbody>
</table>

Adjusted EBITA - organic (non-GAAP)

<table>
<thead>
<tr>
<th>Adjusted EBITA - organic (non-GAAP)</th>
<th>December 31, 2021</th>
<th>December 31, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$ 130.9</td>
<td>$ 110.8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>December 31, 2021</th>
<th>December 31, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>65.4</td>
<td>58.1</td>
</tr>
<tr>
<td>6.8%</td>
<td>7.1%</td>
</tr>
</tbody>
</table>

(1) Organic figures are from existing businesses. Represents total sales less acquisition-related sales in comparison to the portion of the prior period during which we did not own the acquired businesses.

(2) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.

(3) Strategic transaction costs includes costs related to the planned separation.

(4) Includes amortization of acquired intangibles and fair value charges on acquired inventory.

Note: Dollars in millions. Some periods may not foot due to rounding.